Overview

Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
In order to understand how pharmacokinetics and immunological inactivation affect the therapeutic efficacy of Asparaginase (ASP), it is of help and advised in the frame of clinical font-line protocols to monitor the enzymatic activity by measuring the serum ASP levels in the days following the administration of the drug.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Treatments:
Asparaginase